GlassScriptPhysician profile
Samuel Dadzie
NPI 1568858314
$1,194.21
in general payments reported to CMS, 2019-2025
12 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $84.02 · 2021: $305 · 2022: $257 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $415.30 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $150.61 | 2019-2021 | |
| Vifor Pharma, INC. | $136.42 | 2019-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $116.74 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $111.00 | 2021-2022 | |
| Amgen INC. | $100.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $57.61 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $29.72 | 2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $25.92 | 2025 | |
| La Jolla Pharmaceutical Company | $18.31 | 2020 | |
| Genzyme Corporation | $17.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Dadzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.